Effect of once-daily FDC treatment era on initiation of cART

HIV/AIDS - Research and Palliative Care

Volumn 2, Issue , 2010, Pages 19-26

  Mosen, David M ^a   Horberg, Michael ^b   Roblin, Douglas ^c   Gullion, Christina M ^a   Meenan, Richard ^a   Leyden, Wendy ^b   Hu, Weiming ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b DIVISION OF RESEARCH   (United States)

^c Center for Health Research   (United States)

Author keywords

ARV treatment; ARV na ve; Once daily FDC therapies

Indexed keywords

EID: 77954546317     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/hiv.s8803     Document Type: Review

References (16)

1. Panel on Clinical Practice for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Afr J Med Pract. 1998;5:79-104.
2. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Recomm Rep. 1998;47(RR-5):43-82.
3. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 2002;137(5 Pt 2):381-433.
4. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clini- cal Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommenda- tions of the Panel on Clinical Practices for Treatment of HIV. MMMR Recomm Rep. 2002;51(RR-7):1-55.
5. Tashima KT, Mitty JA. Once-daily therapies for the treatment of HIV infection. HIV/AIDS Rep. 2006;3:86-92.
6. Carey D. Once-daily therapies. J HIV Ther. 2003;8:7-11.
7. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regiments in predicting adherence. J Acquir Immune Defic Syndr. 2004;36:808-816.
8. Sherer RD, Fath MJ, Da Silva BA, et al. The importance of potency and durability in HIV patient antiretroviral therapy preferences: A telephone survey. AIDS Patient Care STDS. 2005;19:794-802.
9. Kitahata M, Van Rompaey S, Shield A. Physicians' experience in the care of HIV-infected persons is associated with earlier adoption of new anti- retroviral therapy. J Acquir Immune Defic Syndr. 2000;24:106-114.
10. Piacenti FJ. An update and review of antiretroviral therapy. Pharmacotherapy. 2006;26:1111-1133.
11. Sax PE, Gathe Jr JC. Beyond efficacy: the impact of combination antiretroviral therapy on quality of life. AIDS Patient Care STDS. 2005;19:563-576.
12. Patterson DL, Windells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
13. Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppres- sion over 3.3 years with multi-drug antiretroviral therapy in previously drug-naïve individuals. AIDS. 2001;15:2379-2384.
14. Tashima, KT, Hogan JF, Gardner LI, et al. A longitudinal analysis of hospitalization and emergency department use among HIV-infected women reporting protease inhibitor use. Clin Infec Dis. 2001;33: 2055-2060.
15. Hammer SM, Saag MS, Schecter M, et al. Treatment of adult HIV Infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-843.
16. Kitihata MM, Gange SJ, Moore RD. Initiation Rather than Deferring HAART at a CD4 Count Between 351-500 Cells/mm is Associated with Improved Survival. Washington, D.C.: Presented at 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008.